KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX), a leader in drug delivery platforms, has initiated a 12-week animal study, named WEIGHT-A24-1, to evaluate the effectiveness of its DehydraTECH™ technology in enhancing the delivery of GLP-1 drugs and CBD for the treatment of diabetes and weight loss. The study commenced dosing diabetic preconditioned rats with various DehydraTECH-processed compounds to determine the potential benefits in brain absorption, weight loss, and blood sugar control.
The study comprises twelve arms, including two that for the first time will assess DehydraTECH-processed semaglutide and liraglutide, comparing them with reformulated Rybelsus® that incorporates Novo Nordisk (NYSE:NVO)'s SNAC® technology. Additionally, the study will investigate the effects of combining DehydraTECH-processed CBD with these compounds. The first eight arms of the study are currently underway, and the remaining four arms will begin following the initial phase's completion.
During the study, over 1,500 blood plasma samples will be collected for pharmacokinetic analyses. Regular measurements of body weight and blood glucose levels will be taken, and upon conclusion, brain tissue analysis will be conducted to determine if DehydraTECH processing leads to increased brain absorption of the drugs. The study also includes extensive testing for liver and kidney function and blood chemistry.
Lexaria’s DehydraTECH platform is known for improving the bio-absorption of active pharmaceutical ingredients (APIs) and has shown promise in delivering drugs more effectively across the blood-brain barrier. The company has conducted similar research with other molecules, including CBD, which demonstrated increased levels of drug delivery into brain tissue. If DehydraTECH processing of GLP-1 drugs shows similar results, it could potentially enhance the drugs' effectiveness in weight loss and blood sugar control, possibly allowing for lower dosing and reduced side effects.
InvestingPro Insights
Lexaria Bioscience Corp. (NASDAQ:LEXX) is garnering attention with its innovative DehydraTECH™ technology, aiming to revolutionize drug delivery for diabetes and weight loss treatments. As investors evaluate Lexaria's potential, InvestingPro data provides a snapshot of the company's financial health and market performance.
InvestingPro data indicates a market capitalization of $40.46 million, reflecting the company's current valuation in the market. Despite challenges, the company holds a strong cash position relative to its debt, which is an encouraging sign for investors considering the financial stability of Lexaria. Additionally, the company's revenue growth has been impressive, with a quarterly increase of 624.09% as of the last twelve months ending in Q2 2024, showcasing the company's ability to expand its sales significantly.
On the performance front, Lexaria's stock has experienced a significant price uptick, with a 139.71% return over the last six months and an even more remarkable year-to-date price total return of 151.2% as of the same period. This demonstrates strong market confidence and a positive reaction to the company's strategic initiatives and research progress.
InvestingPro Tips highlight that analysts are optimistic about Lexaria's sales growth in the current year, which aligns with the company's revenue growth data. However, they also caution that analysts do not anticipate the company will be profitable this year, and the stock has recently taken a hit, with an 11.55% decline over the last week.
For those looking to delve deeper into Lexaria's prospects, InvestingPro offers additional insights, with a total of 12 InvestingPro Tips available for the company. By using the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription, providing access to comprehensive analysis and actionable investment strategies.
With its strong intellectual property portfolio and ongoing research initiatives, Lexaria Bioscience Corp. is positioned at the forefront of drug delivery technology. As the company continues to explore the capabilities of DehydraTECH™, investors will be watching closely to see how these developments translate into financial performance and market growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.